These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36657323)

  • 1. A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome.
    Hamacher R; Liu X; Schuler MK; Hentschel L; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner L; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Kunitz A; Grünwald V
    Eur J Cancer; 2023 Mar; 181():145-154. PubMed ID: 36657323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
    Karch A; Koch A; Grünwald V
    Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
    Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
    J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
    Weiss AR; Chen YL; Scharschmidt TJ; Chi YY; Tian J; Black JO; Davis JL; Fanburg-Smith JC; Zambrano E; Anderson J; Arens R; Binitie O; Choy E; Davis JW; Hayes-Jordan A; Kao SC; Kayton ML; Kessel S; Lim R; Meyer WH; Million L; Okuno SH; Ostrenga A; Parisi MT; Pryma DA; Randall RL; Rosen MA; Schlapkohl M; Shulkin BL; Smith EA; Sorger JI; Terezakis S; Hawkins DS; Spunt SL; Wang D
    Lancet Oncol; 2020 Aug; 21(8):1110-1122. PubMed ID: 32702309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
    Bilici A; Koca S; Karaagac M; Aydin SG; Eraslan E; Kaplan MA; Ocak B; Goksu SS; Paydas S; Akgul F; Derin S; Ergun Y; Yekeduz E; Erol C; Ozyukseler DT; Demiray AG; Karaca M; Guc ZG; Menekse S; Cinkir HY; Gumusay O; Sakin A; Ozkul O; Demir H; Erdem D; Besiroglu M; Unal OU; Acar R; Koral L; Sahin S; Sakalar T; Bahceci A; Ozveren A; Gunaydin UM; Seker MM; Sunar V; Dal P; Artac M; Turhal S
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8243-8253. PubMed ID: 37067546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.
    Sleijfer S; Rizzo E; Litière S; Mathijssen RHJ; Judson IR; Gelderblom H; Van Der Graaf WTA; Gronchi A
    Acta Oncol; 2018 Aug; 57(8):1117-1126. PubMed ID: 29521151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
    Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
    Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321.
    Gartrell J; Panetta JC; Baker SD; Chen YL; Hawkins DS; Ostrenga A; Scharschmidt TJ; Spunt SL; Wang D; Weiss AR
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):551-557. PubMed ID: 35083502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406).
    Cranmer LD; Lu Y; Heise RS; Ballman KV; Loggers ET; Pollack SM; Wagner MJ; Reinke DK; Schöffski P; Tap WD
    Clin Cancer Res; 2023 Mar; 29(6):1068-1076. PubMed ID: 36622694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
    Sharma A; Kataria B; Biswas B; Bakhshi S; Pushpam D
    J Oncol Pharm Pract; 2022 Apr; 28(3):560-568. PubMed ID: 33719725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
    Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
    Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: Are Indian patients different?
    Sharma A; Vanidassane I; Aggarwal A; Mridha AR; Pandey R; Dhamija E; Barwad A; Rastogi S
    Indian J Cancer; 2019; 56(3):207-210. PubMed ID: 31389382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
    Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
    Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer.
    Doi A; Mizukami T; Takeda H; Umemoto K; Arai H; Horie Y; Izawa N; Ogura T; Sunakawa Y
    Front Oncol; 2023; 13():1110236. PubMed ID: 37324017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
    Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
    Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.